1. Home
  2. NDMO vs IMNM Comparison

NDMO vs IMNM Comparison

Compare NDMO & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest

NDMO

Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest

HOLD

Current Price

$8.81

Market Cap

601.2M

Sector

Finance

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$21.45

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NDMO
IMNM
Founded
N/A
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
601.2M
2.5B
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
NDMO
IMNM
Price
$8.81
$21.45
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
★ $32.80
AVG Volume (30 Days)
281.4K
★ 975.9K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 51.40
EPS
★ N/A
N/A
Revenue
N/A
★ $6,941,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,127.34
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$8.77
$11.09
52 Week High
$10.82
$30.06

Technical Indicators

Market Signals
Indicator
NDMO
IMNM
Relative Strength Index (RSI) 19.61 31.21
Support Level N/A $19.39
Resistance Level $10.47 $23.25
Average True Range (ATR) 0.18 1.19
MACD -0.04 -0.42
Stochastic Oscillator 7.19 1.42

Price Performance

Historical Comparison
NDMO
IMNM

About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest

Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: